Perspective Therapeutics announced that it has initiated clinical trial sites and commenced the enrollment period for its 212Pb-labeled therapeutic product candidates, VMT-alpha-NET and VMT01. “We are excited to have our first clinical sites on board for our two lead development programs and to commence the enrollment period for these promising product candidates in patients with melanoma and neuroendocrine tumors,” said Thijs Spoor, Perspective’s Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CATX:
- Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
- Perspective announces information on Celsium-131 to be presented at ABS
- Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
- Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
- Perspective Therapeutics Reports First Quarter Fiscal 2023 Results